
Commentary|Videos|June 1, 2025
ASCO 2025: Top Data Highlights from 6/1
Author(s)Yan Leyfman, MD, Chandler Park, MD, MSc, FACP
Fact checked by: Kristi Rosa
MedNews Week hosts speak with 5 key opinion leaders at ASCO 2025 about the top data highlights of the day.
Advertisement
On the Clock is a dynamic video series from MedNews Week and OncLive, bringing you rapid-fire insights from top oncology experts at the 2025 ASCO Annual Meeting. In each episode, key opinion leaders share the data they’re most excited about—highlighting the studies, trends, and breakthroughs that could shape clinical practice.
In this episode, hosts Chandler Park, MD, FACP, and Yan Leyfman, MD, spoke with the following key opinion leaders:
- Manmeet Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute
- Michael Wang, MD, of The University of Texas MD Anderson Cancer Center
- Jason Westin, MD, of The University of Texas MD Anderson Cancer Center
- Andrea Necchi, MD, of San Raffaele Hospital and Scientific Institute
- Vivek Patel, MD of Vanderbilt Health
Advertisement
Related to this article

Long-term follow-up showed pTVG-HP nearly doubled median OS compared with placebo in biochemically recurrent prostate cancer.

The FDA has granted fast track designation for safusidenib in IDH1-mutant glioma, with a phase 3 trial on the way.

Dana-Farber research aided in the FDA approval of iberdomide-based therapy in relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.

The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.

Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
2
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
3
Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC
4
Dr Cortés on Developing CD47 as a Biomarker in Pretreated HER2+ Breast Cancer
5





